Education, Science, Technology, Innovation and Life
Open Access
Sign In

Research Progress of Fusobacterium Nucleatum and Colorectal Cancer

Download as PDF

DOI: 10.23977/medsc.2022.030701 | Downloads: 15 | Views: 562


Yuyuan Ma 1, Haijuan Xiao 2


1 The First Clinical Medical College of Shanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712000, China
2 The Third ward of Cancer Hospital of Shanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712000, China

Corresponding Author

Haijuan Xiao


Colorectalcancer (CRC) is one of the common malignancies of the gastrointestinal tract, multiple factors influence its pathogenesis. However, numerous studies have found that Fusobacterium nucleatum(Fn) is highly enriched in tumor microenvironment and fecal samples of CRC patients. Fn participates in and promotes the development of CRC by invading virulence factors, producing proinflammatory microenvironment, and inhibiting immune cell activity. This review provides an overview of the relationship between Fn and CRC by summarizing the existing literature, and provides new ideas for the treatment of CRC in the future.


Fusobacterium Nucleatum, Colorectal Cancer, Intestinal Flora


Yuyuan Ma, Haijuan Xiao, Research Progress of Fusobacterium Nucleatum and Colorectal Cancer. MEDS Clinical Medicine (2022) Vol. 3: 1-6. DOI:


[1] Zhou X, Hu M, Li ZS, et al. Analysis of the epidemic situation of colorectal cancer in the world and China in 2020 [J]. Academic Journal of Naval Medical University:1-9.
[2] Arnold M, Sierra MS, Laversanne M, et al.Global patterns and trends in colorectal cancer incidence and mortality [J]. Gut, 2017, 66(4):683-691.
[3] Tlaskalova-Hogenova H, Vannucci L, Klimesova K, et al.Microbiome and colorectal carcinoma: insights from germ-free and conventional animal models [J].Cancer J,2014,20(3):217-224.
[4] Qin J, Li R, Raes J, et al.A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature, 2010, 464(7285):59-65.
[5] Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut [J]. Nature, 2016, 535(7610):85-93.
[6] Brennan CA, Garrett WS. Gut Microbiota, Inflammation, and Colorectal Cancer [J]. Annu Rev Microbiol, 2016, 70:395-411.
[7] Allen-Vercoe E, Strauss J, Chadee K.Fusobacterium nucleatum: an emerging gut pathogen? [J]. Gut Microbes, 2011, 2(5):294-298.
[8] Kim HS, Lee DS, Chang YH, et al. Application of rpoB and zinc protease gene for use in molecular discrimination of Fusobacterium nucleatum subspecies [J]. J Clin Microbiol, 2010, 48(2): 545-553.
[9] Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body [J]. Nature, 2014, 509(7500): 357-360.
[10] Flynn KJ, Baxter NT, Schloss PD. Metabolic and Community Synergy of Oral Bacteria in Colorectal Cancer [J]. mSphere, 2016,1(3).
[11] Kostic AD, Chun E, Robertson L, et al.Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment [J]. Cell Host Microbe, 2013, 14(2):207-215.
[12] Bullman S, Pedamallu CS, Sicinska E, et al.Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer[J].Science,2017,358(6369):1443-1448.
[13] Castellarin M, Warren RL, Freeman JD, et al.Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma [J].Genome Res,2012,22(2):299-306.
[14] Swidsinski A, Dörffel Y, Loening-Baucke V, et al.Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum[J].Gut,2011,60(1):34-40.
[15] Pascal V, Pozuelo M, Borruel N, et al.A microbial signature for Crohn's disease[J].Gut,2017,66(5):813-822.
[16] Mima K, Cao Y, Chan AT, et al.Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location[J].Clin Transl Gastroenterol,2016,7(11):e200.
[17] Dejea CM, Wick EC, Hechenbleikner EM, et al.Microbiota organization is a distinct feature of proximal colorectal cancers [J].Proc Natl Acad Sci U S A,2014,111(51):18321-18326.
[18] Coppenhagen-Glazer S, Sol A, Abed J, et al.Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth[J].Infect Immun,2015,83(3):1104-1113.
[19] Gur C, Ibrahim Y, Isaacson B, et al.Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack[J].Immunity,2015,42(2):344-355.
[20] Abed J, Emgård JE, Zamir G, et al.Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc[J]. Cell Host Microbe, 2016,20(2):215-225.
[21] Xu M, Yamada M, Li M, et al. FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells[J]. J Biol Chem,2007,282(34):25000-25009.
[22] Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin[J]. Cell Host Microbe,2013,14(2):195-206.
[23] De Martel C, Franceschi S. Infections and cancer: established associations and new hypotheses[J]. Crit Rev Oncol Hematol, 2009, 70(3):183-194.
[24] Ye X, Wang R, Bhattacharya R, et al. Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors[J]. Cancer Prev Res (Phila), 2017, 10(7):398-409.
[25] Park HE, Kim JH, Cho NY, et al.Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma [J]. Virchows Arch, 2017, 471(3):329-336.
[26] Shenker BJ, DiRienzo JM. Suppression of human peripheral blood lymphocytes by Fusobacterium nucleatum[J]. J Immunol, 1984, 132(5):2357-2362.
[27] Shenker BJ, Datar S. Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle [J]. Infect Immun, 1995, 63(12): 4830-4836.
[28] Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours[J]. Nat Rev Immunol, 2012, 12(4): 253-268.
[29] Josefowicz SZ, Lu LF,Rudensky AY. Regulatory T cells: mechanisms of differentiation and function [J]. Annu Rev Immunol, 2012, 30:531-564.
[30] Koch J, Steinle A, Watzl C, et al.Activating natural cytotoxicity receptors of natural killer cells in cancer and infection[J]. Trends Immunol, 2013, 34(4): 182-191.
[31] Seidel E, Glasner A, Mandelboim O.Virus-mediated inhibition of natural cytotoxicity receptor recognition [J]. Cell Mol Life Sci, 2012, 69(23):3911-3920.
[32] Cartwright TH.Treatment decisions after diagnosis of metastatic colorectal cancer [J].Clin Colorectal Cancer, 2012, 11(3):155-166.
[33] Yu T, Guo F, Yu Y, et al.Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy [J]. Cell, 2017, 170(3):548-563.e516.
[34] Koo H, Allan RN, Howlin RP, et al.Targeting microbial biofilms: current and prospective therapeutic strategies [J]. Nat Rev Microbiol, 2017, 15(12):740-755.
[35] Lu SY, Hong J, Chen YX, et al. Study of Fusobacterium nucleatum-related bacterial biofilm promoting M2 polarization of macrophages and chemoresistance in colon cancer [J]. Journal of ShangHai Jiao Tong University (Medical Science), 2020, 40(08):1018-1027.
[36] Eklöf V, Löfgren-Burström A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection [J]. Int J Cancer, 2017, 141(12):2528-2536.
[37] Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia [J]. Gut,2017,66(8):1441-1448.
[38] Liang Q, Chiu J, Chen Y, et al.Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer[J]. Clin Cancer Res,2017,23(8):2061-2070.
[39] Wang HF, Li LF, Guo SH, et al. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer [J]. Sci Rep,2016,6:33440.

Downloads: 4921
Visits: 217938

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.